Previous studies have shown a decrease in cervical cancer associated with intrauterine device use. It has been hypothesized that intrauterine device use may alter the natural history of human papillomavirus infections, preempting development of precancerous lesions of the cervix and cervical cancer, but the effect of intrauterine devices on the natural history of human papillomavirus infection and subsequent development of cervical cancer is poorly understood. OBJECTIVE: The purpose of this study was to evaluate the association between intrauterine device use and cervical high-risk human papillomavirus acquisition and clearance. STUDY DESIGN: This is a prospective cohort study conducted from October 2000 through June 2014 among 676 sexually active young women and girls enrolled from family planning clinics in San Francisco, CA. Data were analyzed using a Cox proportional hazards model, including time-varying indicators of intrauterine device use, and adjusting for fixed and time-dependent predictor variables. RESULTS: A total of 85 women used an intrauterine device at some time during follow-up. Among 14,513 study visits, women reported intrauterine device use at 505 visits. After adjusting for potential behavioral confounders, there was no association between intrauterine device use and human papillomavirus acquisition (hazard ratio, 0.50; 95% confidence interval, 0.20e1.23; P ¼ .13) or clearance of human papillomavirus infection (hazard ratio, 1.44; 95% confidence interval, 0.76e2.72; P ¼ .26). CONCLUSION: Current intrauterine device use is not associated with acquisition or persistence of human papillomavirus infection. Intrauterine device use is safe among women and girls with human papillomavirus infections and at risk for human papillomavirus acquisition. Intrauterine device use may play a role further downstream in the natural history of cervical cancer by inhibiting the development of precancerous lesions of the cervix in human papillomaviruseinfected women, or enhancing clearance of established precancerous lesions.
Introduction
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the United States. 1 Persistent cervical infection with a high-risk type of HPV is necessary for the development of cervical cancer. 2 Although HPV vaccination is the only known intervention to prevent HPVassociated precancerous lesions, 3 it has been hypothesized that intrauterine device (IUD) use may alter the natural history of HPV infections, preempting development of precancerous lesions of the cervix and cervical cancer. In fact, a 2011 meta-analysis of 26 studies from around the world demonstrated a statistically significant decrease in cervical cancer associated with IUD use; women who reported ever using an IUD had approximately half the likelihood of being diagnosed with cervical cancer compared with never users after adjusting for lifetime number of screening pap tests. 4 The interpretation of this study is limited since it was cross-sectional and it did not correct for many possible confounders including some sexual and health behaviors. For instance, more intensive screening, diagnosis, and treatment among IUD users compared with nonusers or differential sexual behavior may still have resulted in differing exposure to HPV between IUD users and nonusers. However, on a biological level, it is plausible that IUDs may protect against cervical cancer through their association with inflammation in the genital tract, 5 which may result in rapid clearance of infections and/or protection against initial HPV acquisition. Some studies have shown that cytokine levels are elevated in the setting of persistent HPV infections suggesting that recruitment of immune mediators is necessary for clearance of the virus. 6 Conversely, other studies have shown that chronic inflammation in the setting of HPV promotes development of high-risk premalignant lesions. 7 The effect of inflammation in the genital tract on HPV is complex and there is a paucity of data on the specific effect of IUDs on cervical HPV infection.
The goal of our study was to evaluate the association between IUD use and high-risk HPV acquisition and clearance in a large prospective cohort.
Materials and Methods
This is an analysis of the San Francisco Natural History of HPV Cohort described elsewhere in detail. 8 Briefly, from October 2000 through October 2006, 676 women were enrolled from 2 family planning clinics in San Francisco, CA. Women and girls ages 13-22 years with <5 years of sexual experience were included. Those who were immunosuppressed or had a history of ablation or excision of the cervix were excluded. Participants were followed up until study close in June 2014. Each visit included a speculum examination with collection of cervicovaginal lavages for high-risk HPV testing, and an interviewer-administered questionnaire to obtain information on and a novel Luminex-based approach, PGMY-LX, which was shown to have a sensitivity and specificity comparable to linear array in this population and is described elsewhere in detail. 9 Sexual and substance use behavior and contraceptive use, including IUD use, were assessed by interview-administered questionnaire. IUD use was verified at the time of speculum examination but the type of IUD strings observed were not recorded.
Incident high-risk HPV infection was defined as the first visit where high-risk HPV DNA was detected following at least 2 preceding visits in which high-risk HPV DNA was not detected. Multiple episodes of acquisition were not allowed for this analysis. Time to high-risk HPV acquisition was defined as the time from first visit with no high-risk HPV DNA detection to first high-risk HPV detection.
HPV clearance was defined as having 2 visits negative for all high-risk HPV types following a visit with a positive high-risk HPV type. Time to high-risk HPV clearance was defined as the time from first high-risk HPV DNA detection to first of 2 negative visits. Prevalent infections detected at baseline were included in the clearance analysis but not the acquisition analysis.
Initial analyses focused on descriptive comparisons of baseline characteristics between women classified as ever users and nonusers of IUDs (or women who did not use an IUD ever during study follow-up). Significance testing was based on the c 2 /Fisher exact test for categorical and the t test/Wilcoxon rank sum test for continuous characteristics.
We considered 2 complementary approaches to investigating the association between IUD use and HPV outcomes: The first was based on a new user design. 10 A new user design identifies all of the participants in a population who start a course of treatment and study follow-up begins at the same time as initiation of the treatment. The goal of this approach is to mimic trial assignment. The rationale is to attempt to balance possibly time-varying confounding factors between users and nonusers, similar to what might be achieved in a randomized trial. Results from observational data analyzed using a new users design were shown to be similar to data from randomized trials. 10 We matched each IUD user to 5 women who were not using IUDs based on user's age and date of IUD initiation. IUD initiation date was estimated within 3 months. IUD users contribute data beginning at the time they initiated their IUD (or on entry into the study if they had an IUD at baseline).
The outcomes were clearance for those who were HPV positive and acquisition for those who were HPV negative following initiation of the IUD (or start date for matched control). Between-group comparisons of cumulative outcome risks were based on Kaplan-Meier estimates and log-rank tests.
Because the new user approach uses only a subset of available data, and does not allow explicit control for time variation in IUD use and other variables potentially related to HPV outcomes, we also analyzed data from the entire cohort using a Cox proportional hazards model, including time-varying indicators of IUD use, and adjusting for fixed and time-dependent predictor variables including age at baseline, age at first intercourse, STI during study follow-up, HPV vaccination status, condom use since last visit, new partner since the last visit, combined hormonal contraceptive use (pill, patch, and ring), smoking since last visit, and pregnancy.
Statistical analysis was performed using software (SAS, Version 9.4; SAS Institute Inc, Cary, NC).
Participants gave written consent according to guidelines approved by the Committee for Human Research, University of California, San Francisco (ClinicalTrials.gov NCT01366742). Table 1 describes the baseline characteristics of the entire cohort by IUD use; 591 women never used an IUD and 85 women used an IUD some time during study follow-up. Among 14,513 study visits, women reported IUD use at 505 visits.
Results
Women who used an IUD were slightly younger at enrollment, younger at first intercourse, more likely to have been pregnant, more likely to identify as white or Latina, and less likely to identify as black, Asian/Pacific Islander, or mixed. There were no other statistically significant differences in baseline characteristics between ever and never users of the IUD.
In the Kaplan-Meier analysis there was a trend toward IUD use being associated with lower high-risk HPV acquisition but this difference was not statistically significant (P ¼ .10) (Figure 1 ). The biggest difference was seen at around 3 years when 28% of IUD users acquired a new high-risk HPV infection vs 42% of non-IUD users.
Similar to the Kaplan-Meier analysis, in the unadjusted Cox proportional hazards model there was a trend toward IUD use being protective against HPV acquisition (Table 2) . Women with an IUD had 0.48 times the rate of any HPV acquisition compared to those without an IUD [CI] (0.23-1.02; P ¼ .057). After adjusting for potential confounders (age at baseline, age at first intercourse, STI during study follow-up, HPV vaccination status, condom use since last visit, new partner since the last visit, combined contraceptive use, smoking since last visit, and pregnancy) the reduced risk of HPV acquisition in IUD users was not statistically significant although the direction of the association remained the same (hazard ratio [HR], 0.50; 95% confidence interval [CI], 0.20e1.23; P ¼ .13).
In the Kaplan-Meier analysis there was no difference in clearance of all highrisk HPV infections when comparing IUD users to nonusers (P ¼ .15) (Figure 2) . By 5 years, all IUD users and most of the non-IUD users had cleared their high-risk HPV infections. For example, at 5 years 100% of IUD users and 77% of non-IUD users cleared their HPV infection.
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There was no association between IUD use and HPV clearance in the unadjusted Cox proportional hazards model (HR, 0.75; 95% CI, 0.48e1.18; P ¼ .21) or after adjusting for potential confounders (age at baseline, age at first intercourse, STI during study follow-up, HPV vaccination status, condom use since last visit, new partner since the last visit, combined contraceptive use, smoking since last visit, and pregnancy) (HR, 1.44; 95% CI, 0.76e2.72; P ¼ .26) ( Table 3 ). Of cases, 24% included in the clearance analysis were prevalent. In a model excluding prevalent cases, after adjusting for the same potential behavioral confounders, there was no association between IUD use and HPV clearance (HR, 1.46; 95% CI, 0.77e2.75; P ¼ .24).
To further investigate the apparent difference in the magnitude and direction of the effect of IUD use on HPV clearance between the marginal and adjusted associations presented in Table 3 , we conducted a sensitivity analysis in which adjustment covariates were added singly to a model already including IUD use. This revealed that condom use was the only adjustment variable that had an appreciable effect on the estimated HR for IUD use. However, because of the substantial overlap in the 95% CI for these 2 estimates, definitive conclusions about possible confounding are not possible.
Comment
This study further supports the safety of IUD use among women and girls with HPV infections and at risk for HPV acquisition. Current IUD use was not associated with persistence of high-risk HPV infections in this cohort. This finding is consistent with other prospective longitudinal studies that also observed no association between IUD use and HPV persistence. [11] [12] [13] [14] We also found that current IUD use was not associated with HPV acquisition. It is certainly possible that a larger study might lead to more precise and significant findings supporting that IUD use is protective against HPV acquisition if the direction and magnitude of our estimated effects was maintained. The strengths of this study include the longitudinal design, which allowed for many women-years of observation, and the fact that the exposure variable (IUD use) was collected prior to determination of the outcome (HPV clearance or acquisition). Also, frequent study visits were conducted allowing for a precise determination of the time-dependent exposure and outcome variables, IUD use, HPV acquisition, and clearance as well as detailed sexual behavior that allowed us to identify potential confounding factors.
The main limitation of our study was the inability to differentiate between levonorgestrel-releasing and copper IUDs. Other studies have suggested that the effect of these IUDs on HPV biology may be different. 15 Our study was conducted among young women in the United States, and most of the IUD use was in the late 2000s, therefore many of our IUD users were likely using levonorgestrel-releasing IUDs. Older studies, including the metaanalysis showing that IUDs are associated with decreased risk of cervical cancer, 4 likely included mostly copper IUDs. If only copper IUDs, which evoke a significant inflammatory response, 16 are effective at preventing cervical cancer, then our findings evaluating HPV acquisition for both types of IUD together may underestimate the effectiveness of copper IUDs. In addition, women who ever used an IUD were more likely to have ever been pregnant compared to women who never used an IUD. This suggests that selection bias may limit the generalizability of the findings to nulliparous women. For this reason, previous pregnancy was included in the multivariate model. History of pregnancy, however, was not independently associated with acquisition or clearance of HPV.
If IUDs are, in fact, causally associated with decreased risk of cervical cancer, the question remains as to the precise link(s) in the chain of events within the natural history from high-risk HPV infection to cervical cancer that IUDs affect. There are several plausible biological mechanisms by which IUDs may exert a protective effect other than decreased acquisition or enhanced clearance of HPV infections. IUD may play a role further downstream in the natural history by inhibiting the development of precancerous lesions of the cervix in HPV-infected women, or enhancing clearance of established precancerous lesions. As we did not have enough cases of cervical intraepithelial neoplasia grade 2/3 in this cohort, we were unable to examine these potential associations.
To our knowledge, this is the first study examining the role of IUD use in Time to HR-HPV clearance among IUD users compared to nonusers. Between-group comparisons of cumulative outcome risks were based on Kaplan-Meier estimates and log-rank tests. Original Research GYNECOLOGY ajog.org
